Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Garry G Graham

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Cancer Research|October 7, 2004
Oncogenic action of secreted phospholipase A2 in prostate cancerPaul Sved, Kieran F Scott, Duncan McLeod, et al.
Alimentary Pharmacology & Therapeutics|January 22, 2020
The safety and pharmacokinetics of metformin in patients with chronic liver diseaseFelicity C Smith, Sophie L Stocker, Mark Danta, et al.
British Journal of Clinical Pharmacology|September 1, 2019
Is the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysisChristina Abdel Shaheed, Jane E Carland, Garry G Graham, et al.
Clinical Pharmacokinetics|March 12, 2013
Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal functionJanna K Duong, Shaun S Kumar, Carl M Kirkpatrick, et al.
Clinical Pharmacokinetics|January 19, 2011
Clinical pharmacokinetics of metforminGarry G Graham, Jeroen Punt, Manit Arora, et al.
The Journal of Biological Chemistry|November 12, 2010
A bifunctional role for group IIA secreted phospholipase A2 in human rheumatoid fibroblast-like synoviocyte arachidonic acid metabolismKatherine J Bryant, Matthew J Bidgood, Pei-Wen Lei, et al.
Molecules (Basel, Switzerland)|December 10, 2021
Human Group IIA Phospholipase A<sub>2</sub>-Three Decades on from Its DiscoveryKieran F Scott, Timothy J Mann, Shadma Fatima, et al.
Biochemical Pharmacology|December 9, 2009
Acetaminophen (paracetamol) inhibits myeloperoxidase-catalyzed oxidant production and biological damage at therapeutically achievable concentrationsMaud Koelsch, Roger Mallak, Garry G Graham, et al.
Annals of the Rheumatic Diseases|August 14, 2014
Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysinWen-Hung Chung, Wan-Chun Chang, Sophie L Stocker, et al.
Cell Death & Disease|December 20, 2025
Targeting secreted PLA<sub>2</sub> interactions with EGFR and vimentin to arrest prostate tumour growthTimothy J Mann, Ryung Rae Kim, Mila Sajinovic, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Cancer Research|October 7, 2004
Oncogenic action of secreted phospholipase A2 in prostate cancerPaul Sved, Kieran F Scott, Duncan McLeod, et al.
Alimentary Pharmacology & Therapeutics|January 22, 2020
The safety and pharmacokinetics of metformin in patients with chronic liver diseaseFelicity C Smith, Sophie L Stocker, Mark Danta, et al.
British Journal of Clinical Pharmacology|September 1, 2019
Is the use of metformin in patients undergoing dialysis hazardous for life? A systematic review of the safety of metformin in patients undergoing dialysisChristina Abdel Shaheed, Jane E Carland, Garry G Graham, et al.
Clinical Pharmacokinetics|March 12, 2013
Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal functionJanna K Duong, Shaun S Kumar, Carl M Kirkpatrick, et al.
Clinical Pharmacokinetics|January 19, 2011
Clinical pharmacokinetics of metforminGarry G Graham, Jeroen Punt, Manit Arora, et al.
The Journal of Biological Chemistry|November 12, 2010
A bifunctional role for group IIA secreted phospholipase A2 in human rheumatoid fibroblast-like synoviocyte arachidonic acid metabolismKatherine J Bryant, Matthew J Bidgood, Pei-Wen Lei, et al.
Molecules (Basel, Switzerland)|December 10, 2021
Human Group IIA Phospholipase A<sub>2</sub>-Three Decades on from Its DiscoveryKieran F Scott, Timothy J Mann, Shadma Fatima, et al.
Biochemical Pharmacology|December 9, 2009
Acetaminophen (paracetamol) inhibits myeloperoxidase-catalyzed oxidant production and biological damage at therapeutically achievable concentrationsMaud Koelsch, Roger Mallak, Garry G Graham, et al.
Annals of the Rheumatic Diseases|August 14, 2014
Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysinWen-Hung Chung, Wan-Chun Chang, Sophie L Stocker, et al.
Cell Death & Disease|December 20, 2025
Targeting secreted PLA<sub>2</sub> interactions with EGFR and vimentin to arrest prostate tumour growthTimothy J Mann, Ryung Rae Kim, Mila Sajinovic, et al.
Pageof 5